Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)

NCT03041311 is registered in ClinicalTrials.gov with G1 Therapeutics, Inc. as lead sponsor.

NCT NCT03041311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03041311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Lead sponsor
G1 Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 29, 2017
Completion date
October 29, 2020
Enrollment
107 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer